Cancer Cachexia-Pipeline Review, H1 2015

Cancer Cachexia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6156IDB
  • |
  • Pages: 118
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cancer Cachexia-Pipeline Review, H1 2015


Global Markets Direct's, 'Cancer Cachexia-Pipeline Review, H1 2015', provides an overview of the Cancer Cachexia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cancer Cachexia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cancer Cachexia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cancer Cachexia Overview 9

Therapeutics Development 10

Pipeline Products for Cancer Cachexia-Overview 10

Pipeline Products for Cancer Cachexia-Comparative Analysis 11

Cancer Cachexia-Therapeutics under Development by Companies 12

Cancer Cachexia-Therapeutics under Investigation by Universities/Institutes 15

Cancer Cachexia-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Cancer Cachexia-Products under Development by Companies 19

Cancer Cachexia-Products under Investigation by Universities/Institutes 21

Cancer Cachexia-Companies Involved in Therapeutics Development 22

Acacia Pharma Ltd. 22

Aeterna Zentaris Inc. 23

Amgen Inc. 24

Aphios Corporation 25

Atara Biotherapeutics, Inc. 26

Eli Lilly and Company 27

GTx, Inc. 28

Helsinn Healthcare S.A. 29

Incyte Corporation 30

Novartis AG 31

Ohr Pharmaceutical Inc. 32

PsiOxus Therapeutics, Ltd. 33

Radius Health, Inc. 34

RaQualia Pharma Inc. 35

Vicus Therapeutics, LLC 36

Cancer Cachexia-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Combination Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

(etodolac + propranolol hydrochloride)-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

(formoterol fumarate + megestrol acetate)-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

anamorelin hydrochloride-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

ATA-842-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

bimagrumab-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

DCB-CA2-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

dronabinol-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Drug to Antagonize ActRIIB for Cancer Cachexia-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

enobosarm-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Espindolol-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

EXT-400-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

LY-2495655-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

macimorelin acetate-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

NBD Peptide-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

OHR/AVR-118-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

RAD-140-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

RQ-00432933-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

ruxolitinib phosphate-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Synthetic Peptides for Cancer Cachexia-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

VK-5211-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Cancer Cachexia-Recent Pipeline Updates 85

Cancer Cachexia-Dormant Projects 104

Cancer Cachexia-Discontinued Products 106

Cancer Cachexia-Product Development Milestones 107

Featured News & Press Releases 107

Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology 107

Dec 11, 2013: Phase II Data on OHR/AVR118 in Advanced Cancer Patients With Cachexia Presented at International Cachexia Conference in Kobe, Japan 108

Oct 24, 2013: GTx Presents Results from Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer at 15th World Conference on Lung Cancer 109

Mar 21, 2013: Ohr Pharma Announces Results From OHR/AVR118 Phase II Trial In Cancer Cachexia 110

Mar 14, 2013: GTx Announces Publication Of Enobosarm Phase II Trial Results In The Lancet Oncology 111

Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102 113

Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology 113

Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 114

Jun 25, 2012: GTx Announces Presentation On Enobosarm's Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels 115

Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 116

Appendix 117

Methodology 117

Coverage 117

Secondary Research 117

Primary Research 117

Expert Panel Validation 117

Contact Us 117

Disclaimer 118

List of Tables

Number of Products under Development for Cancer Cachexia, H1 2015 10

Number of Products under Development for Cancer Cachexia-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Cancer Cachexia-Pipeline by Acacia Pharma Ltd., H1 2015 22

Cancer Cachexia-Pipeline by Aeterna Zentaris Inc., H1 2015 23

Cancer Cachexia-Pipeline by Amgen Inc., H1 2015 24

Cancer Cachexia-Pipeline by Aphios Corporation, H1 2015 25

Cancer Cachexia-Pipeline by Atara Biotherapeutics, Inc., H1 2015 26

Cancer Cachexia-Pipeline by Eli Lilly and Company, H1 2015 27

Cancer Cachexia-Pipeline by GTx, Inc., H1 2015 28

Cancer Cachexia-Pipeline by Helsinn Healthcare S.A., H1 2015 29

Cancer Cachexia-Pipeline by Incyte Corporation, H1 2015 30

Cancer Cachexia-Pipeline by Novartis AG, H1 2015 31

Cancer Cachexia-Pipeline by Ohr Pharmaceutical Inc., H1 2015 32

Cancer Cachexia-Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 33

Cancer Cachexia-Pipeline by Radius Health, Inc., H1 2015 34

Cancer Cachexia-Pipeline by RaQualia Pharma Inc., H1 2015 35

Cancer Cachexia-Pipeline by Vicus Therapeutics, LLC, H1 2015 36

Assessment by Monotherapy Products, H1 2015 37

Assessment by Combination Products, H1 2015 38

Number of Products by Stage and Target, H1 2015 40

Number of Products by Stage and Mechanism of Action, H1 2015 42

Number of Products by Stage and Route of Administration, H1 2015 44

Number of Products by Stage and Molecule Type, H1 2015 46

Cancer Cachexia Therapeutics-Recent Pipeline Updates, H1 2015 85

Cancer Cachexia-Dormant Projects, H1 2015 104

Cancer Cachexia-Dormant Projects (Contd..1), H1 2015 105

Cancer Cachexia-Discontinued Products, H1 2015 106

List of Figures

Number of Products under Development for Cancer Cachexia, H1 2015 10

Number of Products under Development for Cancer Cachexia-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 37

Number of Products by Top 10 Targets, H1 2015 39

Number of Products by Stage and Top 10 Targets, H1 2015 39

Number of Products by Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Top 10 Routes of Administration, H1 2015 43

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 43

Number of Products by Top 10 Molecule Types, H1 2015 45

Number of Products by Stage and Top 10 Molecule Types, H1 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Acacia Pharma Ltd.

Aeterna Zentaris Inc.

Amgen Inc.

Aphios Corporation

Atara Biotherapeutics, Inc.

Eli Lilly and Company

GTx, Inc.

Helsinn Healthcare S.A.

Incyte Corporation

Novartis AG

Ohr Pharmaceutical Inc.

PsiOxus Therapeutics, Ltd.

Radius Health, Inc.

RaQualia Pharma Inc.

Vicus Therapeutics, LLC

Cancer Cachexia Therapeutic Products under Development, Key Players in Cancer Cachexia Therapeutics, Cancer Cachexia Pipeline Overview, Cancer Cachexia Pipeline, Cancer Cachexia Pipeline Assessment

select a license

Single User License
USD 2000 INR 136780
Site License
USD 4000 INR 273560
Corporate User License
USD 6000 INR 410340



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]